Close
28/05/2015
Synchrotron light applications for the pharmaceutical industry
More than forty people from the pharmaceutical sector attended the workshop organised by the ALBA Synchrotron on May 7.

Researchers from the MSPD, CLAESS, XALOC, NCD and MISTRAL ALBA beam lines have shown the available state-of-the-art techniques and the advantages that they offer in this field: fast data acquisition and shorter experiments, cost savings and, in the case of X-ray microscopy, suppression of ethical conflicts because this technique can be a previous step before clinical essays with animals and persons.

The companies Enantia and Almirall, which have already collaborated with the ALBA Synchrotron, have commented their own experiences at the facility. Enantia, specialised in research solutions for other companies, has detailed different examples. For Almirall, the analysis of polymorphic compounds – performed at ALBA – has increased its quality control, verifying and quantifying purity grades.

News based on the press release issued by the ALBA synchrotron.

Image: ALBA synchrotron. Structure of a herpesvirus nuclease-antiviral complex. Data collected at the Xaloc beam line (Bongarzone, S., Nadal, M. & Coll, M., IBMB)

More news

09/12/2014 ADAM involved in the project of shared DC between Malaysia and Catalonia 02/12/2014 ESADE, 4th best business school in Europe 25/11/2014 Nanoparticle technology triples the production of biogas 13/11/2014 A little piece of SENER on comet 67P 05/11/2014 New catalysts investigated with the ALBA Synchrotron 04/11/2014 SENER hosts a meeting with ESA, NASA and ROSKOSMOS in its offices in BSP
36 37 38 39 40 41 42 43 44 45 46